TLR9-based immunotherapy for the treatment of allergic diseases

Farrokhi,, Shokrollah and Abbasirad,, Narjes and Movahed,, Ali and Khazaei,, Hossein Ali and Pishjoo,, Masoud and Rezaei,, Nima (2017) TLR9-based immunotherapy for the treatment of allergic diseases. Immunotherapy, 9 (4). pp. 339-349.

Full text not available from this repository.
Official URL: https://www.ncbi.nlm.nih.gov/pubmed/28303762

Abstract

Toll-like receptors (TLRs), a family of pattern recognition receptors expressed on many cell types of innate immunity, recognize the pathogen-associated molecular patterns of microbes. The hygiene hypothesis suggests that a reduced microbial exposure in early childhood increases the susceptibility to allergic diseases due to deviation in development of the immune system. TLRs are key roles in the right and healthy direction of adaptive immunity with the induction of T-helper 2 toward Th1 immune responses and regulatory T cells. TLR ligand CpG-ODN-based immunomodulation is independent of allergen and it mainly affects innate immune system. While, CpG-oligodeoxynucleotide-based vaccination is allergen specific and induces adaptive immune system. The use of agonists of TLR9 in two distinct strategies of immunotherapy, immunomodulation and vaccination, could be presented as the curative method for the treatment of allergic diseases.

Item Type: Article
Subjects: QW Microbiology and Immunology
Divisions: Research Center > The Persian Gulf Tropical Medicine Research Center
Depositing User: سپیده مقدسی
Date Deposited: 31 Dec 2018 08:34
Last Modified: 31 Dec 2018 08:34
URI: http://eprints.bpums.ac.ir/id/eprint/7421

Actions (login required)

View Item View Item